-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HmBKsnJ0RiPrM7gJirVE2oe8DqFbRVbnCN+so4MHxNl2iP0b24ExbAsYzt9BrBYB
 Ehk17HyfDwFL4JMr+yTWUw==

<SEC-DOCUMENT>0000927946-04-000209.txt : 20040922
<SEC-HEADER>0000927946-04-000209.hdr.sgml : 20040922
<ACCEPTANCE-DATETIME>20040922150216
ACCESSION NUMBER:		0000927946-04-000209
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20040917
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040922
DATE AS OF CHANGE:		20040922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		041041105

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bas8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>

<HTML>
<HEAD>
<TITLE>Form 8-K - Bioanalytical Systems, Inc.</TITLE>
</HEAD>
<BODY>


<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549<BR>
<BR>
FORM 8-K<BR>
<BR>
CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<BR>
<BR>
Date of Report (Date of earliest event reported): September 17, 2004
</font></P>
<BR>


<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>

<TD align=center colspan=3 WIDTH=33%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
BIOANALYTICAL SYSTEMS, INC.<hr width=250>
(Exact name of registrant as specified in its charter)
</FONT></TD></tr>

<TR>
<TD>&nbsp;</td>
</TR>



<TR VALIGN=TOP>
<TD align=center WIDTH=34%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Indiana<HR width=100>
(State or other<BR>
jurisdiction of<BR>
incorporation or<BR>
organization)</FONT></TD>

<TD align=center WIDTH=33%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
0-23357<hR width=150>
(Commission File Number)
</FONT></TD>

<TD align=center WIDTH=33%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
35-1345024<HR width=150>
(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD align=center WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2701 KENT AVENUE<BR>
WEST LAFAYETTE, INDIANA<HR width=250>
(Address of principal executive offices)
</FONT></TD>
<TD align=center WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
47906-1382<HR width=100>
(Zip Code)
</FONT></TD>
</TR>
</TABLE>
<BR>
<BR>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
Registrant's telephone number, including area code:&nbsp;&nbsp;(765)
463-4527</font></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):</font></P>



<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=4>&#144;</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Written communication pursuant to Rule 425 under the Securities Act (17 CFR
234.425)
</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=4>&#144;</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
</FONT></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=4>&#144;</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
</FONT></TD>
</TR>
</TABLE>
<BR>



<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=5%><FONT FACE="Times New Roman, Times, Serif" SIZE=4>&#144;</FONT></TD>
<TD WIDTH=95%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
</FONT></TD>
</TR>
</TABLE>
<BR>






<PAGE>



<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 1.02.&nbsp;&nbsp;&nbsp;&nbsp;Termination of a Material Definitive
Agreement.</font></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September 17, 2004, The Kevin
F. Donohoe Company (&#147;Donohoe&#148;) delivered notice to Bioanalytical
Systems, Inc. (the &#147;Company&#148;) that Donohoe was exercising its right to
terminate the Purchase and Sale Agreement between PKLB Limited Partnership, a
wholly-owned subsidiary of the Company, and Donohoe dated July 26, 2004. The
Purchase and Sale Agreement provided for the sale by PKLB Limited Partnership of
the parcel of land situated at 300-306 West Fayette Street, Baltimore City,
Maryland and the building located thereon. Pursuant to Section 3.2 of the
Purchase and Sale Agreement, Donohoe terminated the agreement based on its right
to terminate in the event that Donohoe determined (in its sole and absolute
discretion) that the property is not suitable for Donohoe&#146;s purposes.</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Project" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<I>The information in Items 7.01 and 9.01 of this Form 8-K is being furnished
and shall not be deemed &#147;filed&#148; for the purpose of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. The information in this Form 8-K shall not be
incorporated by reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended.</I></FONT></P>

<!-- MARKER FORMAT-SHEET="Head Indent 5 Italics" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 7.01.&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Project" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September 22, 2004, the
Company issued a press release announcing the termination of the Purchase and
Sale Agreement between PKLB Limited Partnership, a wholly-owned subsidiary of
the Company, and Donohoe dated July 26, 2004. The full text of the press release
is attached hereto as Exhibit 99.1.</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Indent 5 Italics" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Not applicable. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Not applicable. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bioanalytical
Systems, Inc. press release, issued September 22, 2004.</font></P>







<PAGE>




<!-- MARKER FORMAT-SHEET="ARTICLE bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
SIGNATURES</FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.</FONT></P>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;September 22, 2004</FONT></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc.<BR>
<BR>
<BR>
<BR>

By:&nbsp;&nbsp;/s/&nbsp;Michael R. Cox<hr>
Michael R. Cox<BR>
VP-Finance, Chief Financial Officer and<BR>
Treasurer
</FONT></Td>
</TR>
</TABLE>
<BR>
<PAGE>


<!-- MARKER FORMAT-SHEET="Heading Center Bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit Index</U></FONT></H1>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=10%><div align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit No.</U><BR>
<BR>
99.1</FONT></div></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description</U><BR>
<BR>
Bioanalytical Systems, Inc. press release, issued September 22, 2004.
</FONT></TD>
</TR>
</TABLE>
<BR>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>








<HTML>
<HEAD>
<TITLE>Exhibit 99.1 - Bioanalytical Systems, Inc.</TITLE>
</HEAD>
<BODY>




<P align=center><FONT FACE="Times New Roman, Times, Serif" size=2>
<B><u>Exhibit 99.1</u></B></font></P>


<P ALIGN=right>
<FONT FACE="Times New Roman, Times, Serif" size=1>
<B>FOR MORE INFORMATION:</B>&nbsp;&nbsp;Michael R. Cox
Phone 765.497.5829<BR>
<U>mcox@bioanalytical.com</U><BR>
<B>&#151; OR &#151;</B><BR>
Evan Smith / Erica Pettit<BR>
KCSA Public Relations Worldwide<BR>
212.896.1251 / 212.896.1248<BR>
<B><u>esmith@kcsa.com</u></B> / <B>epettit@kcsa.com</B><BR>
</font></P>
<BR>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B>Bioanalytical Systems, Inc. Announces Delay of Sale-leaseback of Baltimore
Facility</B>
</font></P>
<BR>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
WEST LAFAYETTE, Ind., September 22, 2004&nbsp;&#151;&nbsp;Bioanalytical Systems, Inc.
(Nasdaq:BASI) today announced that it has been notified by the firm with which
it had reached an agreement in principle for the sale and leaseback of its
Baltimore building that the potential buyer is exercising its right to withdraw
from the transaction on the previously announced terms. Michael Cox, CFO,
stated, &#147;There is always risk in non-binding agreements that the parties
will not be able to come to agreement on definitive terms, which has happened.
We remain committed to selling our Baltimore building, on terms which we believe
reflect fair values. At the time we solicited offers for the building, there
were several potential buyers that made offers in a similar range. We have
re-opened discussions with those parties, as well as continuing discussions with
this potential buyer.&#148;</FONT></P>

<!-- MARKER FORMAT-SHEET="Body - No Indent" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Bioanalytical Systems, Inc. is a pharmaceutical development company providing
contract research services and monitoring instruments to the world&#146;s
leading drug development and medical device companies. BASi focuses on
developing innovative services and products that increase efficiency and reduce
costs associated with taking new drugs to market. Visit <U>www.bioanalytical.com</U>
for more about BASi.</FONT></P>
<BR>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=1>
<I>This release contains forward-looking statements that are subject to risks
and uncertainties including, but not<BR>
limited to, risks and uncertainties
related to the development of products and services, changes in technology,
industry standards and regulatory standards,<BR>
and various market and
operating risks detailed in the company&#146;s filings with the Securities and
Exchange Commission.</I></font></P>
<BR>


<!-- MARKER FORMAT-SHEET="Center Rule" FSL="Default" -->
<P ALIGN=CENTER>#&nbsp;#&nbsp;#&nbsp;#&nbsp;#</P>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
